Philip Kestell

Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1<i>H</i>-benzimidazole (ZSTK474)

Gordon W. Rewcastle, Swarna A. Gamage, Jack U. Flanagan et al. · Journal of Medicinal Chemistry · 2011 · 103 citations · Full text

Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability

Liangli Zhao, Lai‐Ming Ching, Philip Kestell et al. · International Journal of Cancer · 2005 · 71 citations

Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients

Francisco Chung, Jun Lu, Brian D. Palmer et al. · Clinical Cancer Research · 2004 · 62 citations

Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans

Jun Lu, Nuala A. Helsby, Brian D. Palmer et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 52 citations

Identification of the Human Liver Cytochrome P450 Isoenzyme Responsible for the 6-Methylhydroxylation of the Novel Anticancer Drug 5,6-Dimethylxanthenone-4-acetic Acid

Shu‐Feng Zhou, James W. Paxton, Malcolm D. Tingle et al. · Drug Metabolism and Disposition · 2000 · 47 citations